INVO Bioscience (INVO Bioscience) Asset Impairment Charge : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is INVO Bioscience Asset Impairment Charge?

INVO Bioscience's Asset Impairment Charge for the three months ended in Dec. 2023 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

INVO Bioscience Asset Impairment Charge Historical Data

The historical data trend for INVO Bioscience's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INVO Bioscience Asset Impairment Charge Chart

INVO Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

0.13

0.09

INVO Bioscience Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

INVO Bioscience Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

INVO Bioscience Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of INVO Bioscience's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

INVO Bioscience (INVO Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » INVO Bioscience Inc (NAS:INVO) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

5582 Broadcast Court, Sarasota, FL, USA, 34240

Website

https://www.invobio.com

INVO Bioscience Inc operates as a medical device company focused on the Assisted Reproductive Technology (ART) marketplace that is creating simplified, lower-cost treatments for patients diagnosed with infertility. The company has developed the INVOcell device and procedure, the first Intravaginal Culture (IVC) system granted FDA clearance in the United States used for the incubation of eggs and sperm during fertilization and early embryo development. The company sells its products to physicians directly; and IVF centers, medical practices, and physicians through distributors.

Executives

Trent D Davis	director	811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot	director	802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum	director	9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren	officer: Chief Financial Officer	110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan	director	22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell	director	61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina	director	5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal	director	INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc.	10 percent owner	527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody	director, officer: Medical Director	1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes	officer: Acting CFO and PFO	1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux	10 percent owner	8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff	director, officer: CEO/Chairman	109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr	officer: Chief Financial Officer	92 GOULD STREET, WAKEFIELD MA 01880